The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
Open accessAbstract
Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases including gastroesophageal reflux disease and secondary prevention of aspirin/NSAID-induced ulcers. Although clinically important adverse effects of PPIs can occur, just as with other drugs, those are not frequently observed during or after administration. Thus, PPIs are regarded as relatively safe and considered to be clinically beneficial. Recently, PPIs have become frequently administered to patients with functional gastrointestinal diseases or primary prevention of drug-related gastroduodenal damage, even though their beneficial effects for those conditions have not been fully confirmed. PPIs tend to be given for conditions in which the necessity of the drug has not been clarified, thus otherwise rare adverse effects are presented as clinically relevant. Although several PPI-related adverse effects have been reported, their clinical relevance is not yet clear, since the evidence reported in those studies is not at a high enough level, as the majority are based on retrospective observational studies and the reported hazard ratios are low. It is important to administer PPIs only for patients who will gain a substantial clinical benefit and to continue to investigate their adverse effects with high quality prospective studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lundell, L. R., Dent, J., Bennett, J. R., Blum, A. L., Armstrong, D., Galmiche, J. P., Johnson, F., Hongo, M., Richter, J. E., Spechler, S. J., et al. (1999) · Gut · doi:10.1136/gut.45.2.172 · Cited by 2,305
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007964 · Cited by 1,240
Ho, P. M. (2009) · JAMA · doi:10.1001/jama.2009.261 · Cited by 1,007
Proton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895
Freedberg, D. E., Kim, L. S., & Yang, Y.-X. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.031 · Cited by 891
Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
Laheij, R. J. F. (2004) · JAMA · doi:10.1001/jama.292.16.1955 · Cited by 877
Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs
Hawkey, C. J., Karrasch, J. A., Szczepañski, L., Walker, D. G., Barkun, A., Swannell, A. J., & Yeomans, N. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381105 · Cited by 863
Kuipers, E. J., Lundell, L., Klinkenberg-Knol, E. C., Havu, N., Festen, H. P. M., Liedman, B., Lamers, C. B. H. W., Jansen, J. B. M. J., Dalenbäck, J., Snel, P., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341603 · Cited by 769
Yeomans, N. D., Tulassay, Z., Juhász, L., Rácz, I., Howard, J. M., van Rensburg, C. J., Swannell, A. J., & Hawkey, C. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381104 · Cited by 767
Metadata
- Authors
- Kinoshita, Y., Ishimura, N., & Ishihara, S.
- Venue
- Journal of Neurogastroenterology and Motility
- Published
- 2018-04-30
- Volume
- 24
- Issue
- 2
- Pages
- 182-196
- ISSN
- 2093-0879 (ISSN-L)
- 2093-0887
- OpenAlex
- W2802722762
- Cited by
- 271
- References
- 124
- FWCI
- 22.21
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. https://app.cochat.ai/papers/10.5056/jnm18001
- The paper
- Kinoshita, Y., Ishimura, N., & Ishihara, S. (2018). Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. Journal of Neurogastroenterology and Motility. https://doi.org/10.5056/jnm18001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.